Aztron Medtech Surpasses 100 U.S. TendMIN® Procedures, Reflecting Sustained Adoption in Minimally Invasive Achilles Tendon Repair

Dr. Brian Burgess completed the 100th minimally invasive Achilles tendon repair using the Aztron Medtech TendMIN® system.

• FDA-listed TendMIN^® system enables percutaneous Achilles tendon repair through an incision of 1 centimeter or less, designed to help reduce soft tissue disruption and infection risk





• More than 100 U.S. clinical procedures completed, reflecting sustained adoption across multiple hospitals and surgical centers beyond the initial pilot phase





• Aztron Medtech is expanding surgeon training, clinical data collection, and U.S. market presence to support broader adoption of minimally invasive Achilles tendon repair

NEWARK, Calif., February 5, 2026 -(BUSINESS WIRE)- Aztron Medtech, a privately held orthopedic device company, today announced that more than 100 clinical procedures have now been performed in the United States using its TendMIN^® Minimally Invasive Achilles Tendon Repair System, marking a significant milestone in the system’s continued clinical adoption.

The 100th U.S. TendMIN^® procedure was performed by Dr. Brian Burgess, DPM, a board-certified podiatric surgeon. “Reaching 100 U.S. cases is an important milestone for both clinical adoption and the continued advancement of minimally invasive Achilles tendon repair,” said Yi-Hsi (Ben) Huang, CEO of Aztron Medtech. “This achievement reflects rapidly growing surgeon utilization of the TendMIN^® system and its ability to deliver a consistent, minimally invasive repair that aligns with modern expectations for patient recovery and surgical efficiency.”

The TendMIN^® system is designed to enable percutaneous Achilles tendon repair through an incision of approximately 1 centimeter or less, allowing surgeons to perform a robust repair while minimizing soft tissue disruption. Published literature on minimally invasive and percutaneous Achilles tendon repair techniques has demonstrated potential benefits, including reduced infection risk, fewer wound complications, and accelerated recovery compared to traditional open repair approaches (Wang et al., 2012, Wang et al., 2024).

Building on this momentum, Aztron Medtech is continuing to expand surgeon training initiatives, support ongoing clinical data collection, and broaden access to the TendMIN^® system across the U.S. foot and ankle, sports medicine, and orthopedic markets.

About Aztron Medtech

Aztron Medtech is a privately held orthopedic device company developing innovative solutions for advancing percutaneous Achilles tendon repair. Its flagship product, TendMIN^® Minimally Invasive Achilles Tendon Repair System, received FDA listing in 2025 and leverages advanced suture-passing and retrieval technology to enable quick, minimally invasive Achilles repair through incisions 1 centimeter or less. Aztron is building a broader platform to support sports medicine and foot and ankle surgery, with a focus on improving clinical outcomes, reducing infection risks, and streamlining surgical workflows. For more information, please visit www.aztron-medtech.com.

Contacts

Aztron Medtech Team
Email: info@aztron-medtech.com